R. CLEMENTE, G. BERSANI- Vol. 10, March 2004, Issue 1
Testo Immagini Bibliografia Summary Indice
Deficit cognitivi nella schizofrenia e profilo
di risposta ai diversi antipsicotici atipici
Cognitive deficits in schizophrenia and profile of response to different
atypical antipsychotics
1 Palmer BW, Heaton RK, Paulsen JS, et al. It is possible to be schizophrenic and neuropsychologically normal? Neuropsychology 1997;11:337-47.
2 Cornblatt BA, Erlenmeyer-Kimling L. Global attentional deviance as a marker of risk for schizophrenia: specificity and predictive validity. J Abnormal Psychol 1985;94:470-86.
3 Crow TJ, Done DJ, Sacker A. Childhood precursor of psychosis as clues to its evolutionary origins. Europ Arch Psych Clin Neurosci 1995;245:61-9.
4 Bilder RM, Lipschutz LB, Reiter G, Geisler SH, Mayerhoff D, Lieberman JA. Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. Schizophr Bull 1992;18:437-48.
5 Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994;51:124-31.
6 Riley EM, McGovern D, Mockler D, Doku V, O’Cealleigh S, Fannon DG, et al. Neuropsychological functioning in first-episode psychosis-evidence of specific deficits. Schizophrenia Research 1999;43:47-55.
7 Green MF. What are the functional consequences of neurocognitiva deficits in schizophrenia? Am J Psychiatry 1996;153:321-30.
8 Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophrenia Bulletin 1990;16:477-99.
9 Medalia A, Gold JM, Merriam A. The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol 1988;3:249-71.
10 Orzack MH, Kornetsky C, Freeman H. The effects of daily administration of carphenazine on attention in the schizophrenic patients. Psychopharmacologia 1967;11:31-8.
11 Sphon HE, LaCoursiere RB, Thompson K, Coyne L. Phenotiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics. Arch Gen Psychiatry 1977;34:633-44.
12 Pigache RM. The clinical relevance of an auditory attention task (PAT) in a longitudinal study of chronic schizophrenia, with placebo substitution for chlorpromazine. Schizophr Res 1993;10:39-50.
13 Levin ED, Wilson W, Rose JE, Mc Evoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996;15:429-36.
14 Gilbertson MW, van Kammen DP. Recent and remote memory dissociation: medication effects and hippocampal function in schizophrenia. Biol Psychiatry 1997;42:585-95.
15 Spiegel DE, Keith-Spiegel P. The effects of carphenazine, trifluoperazine and chlorpromazine on ward behaviour, physiological functioning and psychological test scores in chronic schizophrenic patients. J Nerv Mental Dis 1967;144:111-6.
16 Verdoux H, Magnin E, Bourgeois M. Neuroleptic effects on neuropsychological test performance in schizophrenia. Schizophr Res 1995;14:133-9.
17 Castner CW, Covington CM, Nichols JE. The effects of a Thorazine-centered treatment program with psychological evaluations. Texas Report Biol Med 1958;16:21-30.
18 Abrams J. Chlorpromazine in treatment of chronic schizophrenia. Dis Nerv System 1958;19:20-8.
19 Grygier P, Waters MA. Chlorpromazine used with an intensive occupational therapy program: A controlled study. AMA Arch Neurol Psychiatry 1958;79:697-705.
20 Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown GM. Neuroleptic drug effects on cognitive function in schizophrenia. Schizophr Res 1990;3:211-9.
21 Seidman LJ, Pepple JR, Faraone SV, Kremen WS, Green AI, Brown WA, et al. Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction. Biol Psychiatry 1993;33:575-84.
22 Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 1994;55(9 Suppl B):82-7.
23 Pearl D. Phenotiazine effects in chronic schizophrenia. J Clin Psychol 1962;18:86-9.
24 Killian GA, Holzman PS, Davis JM, Gibbons R. Effects of psychotropic medication on selected cognitive and perceptual measures. J Abnormal Psychol 1984;93:58-70.
25 Allen DN, Gilbertson MW, van Kammen DP, Kelley ME, Gurklis JA, Barry EJ. Chronic haloperidol treatment does not affect structure of attention in schizophrenia. Schizophr Res 1997;25:53-61.
26 Sweeney JA, Keilp JG, Haas GL, Hill J, Seiden PJ. Relationships between medication treatments and neuropsychological test performance in schizophrenia. Psychiatry Res 1991;37:297-308.
27 Zahn TP, Pickar D, Haier RJ. Effects of clozapine, fluphenazine, an placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophr Res 1994;13:133-44.
28 Small IF, Small JC, Milstein V, Moore JE. Neuropsychological observations with psychosis and somatic treatment: neuropsychological examinations of psychiatric patients. J Nerv Mental Dis 1972;155:6-13.
29 Fredericks RS, Finkel P. Schizophrenia performance on the Halstead-Reitan Battery. J Clin Psychol 1978;34:26-30.
30 Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA, et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biological Psychiatry 2002;51:972-8.
31 Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophrenia Bulletin 1999;25:201-22.
32 Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapina on cognitive function in schizophrenia. Schizophr Bull 1999;25:33-255.
33 Kasper S, Resinger E. Cognitive effects and antipsychotic treatment. Psychoneuroendocrinol 2003;28:27-38.
34 Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effects of clozapine treatment on neuropsychological test performance. Biological Psychiatry 1994;36:717-25.
35 Potkin SG, Fleming K, Jin Y, Gulasekaram B. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J Clin Psychopharmacol 2001;21:479-83.
36 Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman N, Sheitman B, et al. Neurocognitive effects of clozapine, olanzapina, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorders. Am J Psychiatry 2002;159:1018-28.
37 Galletly CA, Clark CR, McFarlane AC, Weber DL. Relationships between changes in symptom ratings, neuropsychological test performance, and quality of life in schizophrenic patients with clozapine. Psychiatry Res 1997;72:161-6.
38 Hoff AL, Faustman WO, Wieneke M, Espinoza S, Costa M, Wolkowitz O, et al. The effects of clozapine on symptoms reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacol 1996;15:361-9.
39 Daniel DG, Goldberg TE, Weinberger DR, Kleinman JE, Pickar D, Lubick LJ, et al. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorders: a pilot study. Am J Psychiatry 1996;153:417-9.
40 Meyer-Lindenberg A, Gruppe H, Bauer U, Lis S, Krieger S, Gallhofer B. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry 1997;30:35-42.
41 Lindenmayer JP, Iskander A, Park M, Aspergi FS, Czobor P, Smith R, Allen D. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenics. A prospective study. J Clin Psychiatry 1998;59:521-7.
42 Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapina, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000;57:249-58.
43 Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry 1993;34:702-12.
44 Galletly CA, Clark CR, McFarlane AC, Weber DL. The effects of clozapine on the speed and accuracy of information processing in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2000;24:1329-38.
45 Sharma T, Hughes C, Soni W, Kumari V. Cognitive effects of olanzapina and clozapine treatment in chronic schizophrenia. Psychopharmacology 2003;169:398-403.
46 Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, et al. The effect clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993;162:43-8.
47 Grace J, Bellus SB, Raulin ML, Herz MI, Priest BL, Brenner V, et al. Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psych Serv 1996;47:41-5.
48 Fujii DEM, Ahmed I, Jokumsen M, Compton JM. The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. Journal of Neuropsychiatry 1997;22:240-5.
49 Lee MA, Jayathilake K, Meltzer HY. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr Res 1999;37:1-11.
50 Welsh MC, Pennington BF, Ozonoff S, Rouse B, McCabe ERB. Neuropsychology of early-treated phenilketonuria: specific executive function deficits. Child Development 1990;61:1697-713.
51 Zorn SH, Jones SB, Ward KM, Liston DR. Clozapine is a potent and selective muscarinic M4 receptor agonist. Europ J Pharmacol 1994;269:R1-2.
52 Parada MA, Hernandez L, Puig de Parada M, Rada P, Murzi E. Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum. J Pharmacol Exp Ther 1997;281:582-8.
53 Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 1996;6:14-20.
54 Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapina and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 2001;48:17-28.
55 Kores PB, Zalar B, Tomori M, Krajnc I. Measurement of simple reaction time in antipsychotic treatment of patient with schizophrenia. Wien Klin Wochenschr 2003;115:58-62.
56 Harvey PD, Green MF, McGurk SR, Meltzer HY. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacol 2003;169:311-404.
57 Green MF, Marshall BD, Wirshing WC, Ames D, Marder SR, McGurk SR, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154:799-804.
58 McGurk SR, Green MF, Wirshing WC, Ames D, Marshall BD Jr, Marder AR, et al. The effects of risperidone vs. haloperidol on cognitive functioning in treatment-resistant schizophrenia: the Trail Making Test. CNS Spectrum 1997;2:60-4.
59 Addington J, Addington D. Neurocognitive functioning in schizophrenia. A trial of risperidone versus haloperidol. Canad J Psychiatry 1997;42:983.
60 Kern RS, Green MF, Marshall BD, Wirshing WC, Wirshing D, McGurk SR, et al. Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biological Psychiatry 1998;44:726-32.
61 Kern RS, Green MF, Marshall BD, Wirshing WC, Wirshing D, McGurk SR, et al. Risperidone vs. haloperidol on secondary memory: can newer antipsychotic medications aid learning? Schizophr Bull 1999;25:223-32.
62 Liu SK, Chen WJ, Chang C, Lin H. Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol. Neuropsychopharmacol 2000;22:311-9.
63 Chua L, Chong SA, Pang E, Ng VP, Chan YH. The effect of risperidone on cognitive functioning in a sample of Asian patients with schizophrenia in Singapore. Singapore Med J 2001;42:243-6.
64 Hong KS, Kim JG, Koh HJ, Koo MS, Kim JH, Lee D, et al. Effects of risperidone on information processing and attention in first-episode schizophrenia. Schizophr Res 2002;53:7-16.
65 Borkowska A, Araszkiewicz A, Rajewski A, Rybakowski JK. Risperidone treatment of schizophrenia: improvement in psychopathology and neuropsychological tests. Neuropsychobiol 2002;46:85-9.
66 Stip E, Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Canad J Psychiatry 1996;41(Suppl 2):35-40.
67 Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F, et al. Risperidone, negative symptoms, ad cognitive deficits in schizophrenia: an open study. Acta Psychiatrica Scand 1997;95:40-3.
68 Radziwillowicz P, Radziwillowicz W, Lis J. Effect of olanzapine treatment on cognitive functions in patients with schizophrenia. Psychiatry Polish 2002;36:967-87.
69 Smith RC, Infante M, Singh A, Khandat A. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. J Intern Neuropsychopharmacol 2001;4:239-50.
70 Stip E, Lussier I, Gabai M, Babai M, Fabian JL, Link C. Seroquel and cognitive improvement in patients with schizophrenia. Biological Psychiatry 1996;40:434-5.
71 Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapina or haloperidol. J Psychiatry Neurosci 2001;26:137-49.
72 Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 2002;53:239-48.
73 Velligan DI, Prihoda TJ, Sui D, Ritch JL, Maples N, Miller AL. The effectiveness of quetiapine versus conventional antipsychotic in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry 2003;64:524-31.
74 Sax KW, Strakowski SM, Keck PE Jr. Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophr Res 1998;33:151-5.
75 Good KP, Kiss I, Buiteman C, Woodley H, Whitehorn D. Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. Br J Psychiatry 2002;181(Suppl 43):s45-s49.
76 Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212(Suppl):11.
77 Weiser M, Shneider-Beeri M, Nakash N, Brill N, Bawnik O, Reiss S, et al. Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS? Schizophr Res 2000;46:81-9.
78 Green M, Walker E. Susceptibility to backward masking in schizophrenic patients with positive or negative symptoms. Am J Psychiatry 1984;141:1273-5.
79 Hawkins KA, Hoffman RE, Quinlan DM, Rakfeldt J, Docherty NM, Sledge WH. Cognition, negative symptoms, ad diagnosis: a comparison of schizophrenic, bipolar, and control samples. J Neuropsychiatry Clin Neurosci 1997;9:81-9.
80 Addington J, Addington D. Neurocognitive functioning in first episode schizophrenia. Schizophr Res 1998;29:50.
81 Rollnik JD, Borsutzky M, Huber TJ, Mogk H, Emrich HM, Schneider U. Short-term cognitive improvement in schizophrenics treated with typical and atypical neuroleptics. Neuropsychobiol 2002;45:74-80.
82 Crow TJ. Positive and negative schizophrenic symptom and the role of dopamine. Br J Psychiatry 1980;137:383-6.
83 Liddle PF. The symptoms of chronic schizophrenia. A re-examination of positive and negative dichotomy. Br J Psychiatry 1987;151:145-51.
84 Kendell RE The role of diagnosis in psychiatry. Oxford: Blackwell Scientific Publications 1975.
85 Brown WA, Herz LR. Response to neuroleptic drugs as a device for classifying schizophrenia. Schizophr Bull 1989;15:123-9.
86 Lawrie SM, Ingle GT, Santosh CG, Rogers AC, Rimmington JE, Naidu KP, et al. Magnetic Resonance Imaging and single photon emission tomography in treatment-responsive and treatment-resistant schizophrenia. Br J Psychiatry 1995;167:202-10.
87 Smith RC, Largen J, Vroulis G, Ravichandran GK. Neuropsychological test scores and clinical response to neuroleptic drugs in schizophrenic patients. Comprehensive Psychiatry 1992;33:139-45.
88 Robinson DG, Woerner MG, Avir JM, Geisler S, Koreen A, Sheitman B, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544-9.
89 Smith RC, Kadewari RP, Rosenberger JR, Bhattacharyya A. Nonresponding schizophrenia: differentiation by neurological soft signs and neuropsychological tests. Schizophr Bull 1999;25:813-25.
90 Joober R, Rouleau GA, Lal S, Dixon M, O’Driscoll G, Palmour R, et al. Neuropsychological impairments in neuroleptic responder versus nonresponder schizophrenic patients and healthy volunteers. Schizophr Res 2002;53:229-38.
91 Goldman RS, Axelrod BN, Tandon R, Ribeiro SCM, Craig K, Berent S. Neuropsychological predictors of treatment efficacy and one-year outcome in schizophrenia. Psychopathology 1993;26:122-6.
92 Stip E, Lussier I, Ngan E, Mendrek A, Liddle P: Discriminant cognitive farctors in responder and non responder patients with schizophrenia. Europ Psychiatry 1999;14:442-50.
93 Bartkò G, Frecska E, Horvàth S, Zàdor G, Aratò M. Predicting neuroleptic response from a combination of multilevel variables in acute schizophrenic patients. Acta Psychiatrica Scandinavica 1990;82:408-12.
94 Grawe RW, Levander S. Neuropsychological impairments in patients with schizophrenia: stability and prediction of outcome. Acta Psychiatrica Scandinavica 2001;104(Suppl 408):60-4.
95 Green MF, Kern RS, Braff D, Mintz J. Neurocognition and functional outcome in schizophrenia: are we measuring the right stuff? Schizophr Bull 2000;26:119-36.